Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction

Myung Shik Lee, Lise Wogensen, Judith Shizuru, Michael B.A. Oldstone, Nora Sarvetnick

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

IL-10 inhibits macrophage-dependent antigen presentation, cytokine production, and generation of allospecific cells in vitro. These findings have lead to the widespread expectation that IL-10 may be a useful immunosuppressive agent to inhibit allograft rejection or autoimmunity in vivo. We used two experimental paradigms to study effects of murine IL-10 on in vivo immune responses. First, fetal pancreata or adult pancreatic islets from transgenic mice expressing IL-10 in pancreatic β cells (Ins-IL-10 mice) were grafted across the MHC barrier to examine if IL-10 could inhibit allograft rejection. Second, Ins-IL-10 mice were crossed with transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) antigens in pancreatic β cells. These mice were infected with LCMV to elicit autoimmune diabetes, allowing us to ask if IL-10 protects islets from autoimmune destruction. We observed that allografts from IL-10-transgenic donors were rejected with comparable kinetics to the rejection of control nontransgenic allografts, indicating that IL-10 does not inhibit allograft rejection. After LCMV infection, IL-10 and LCMV antigen double transgenic mice developed diabetes earlier than LCMV antigen single transgenic littermates, suggesting that IL- 10 does not inhibit islet antigen presentation or recognition. Our results contrast to in vitro observations and suggest that IL-10 cannot overcome immune-mediated tissue destruction within the pancreas.

Original languageEnglish (US)
Pages (from-to)1332-1338
Number of pages7
JournalJournal of Clinical Investigation
Volume93
Issue number3
DOIs
StatePublished - Mar 1994

Fingerprint

Islets of Langerhans
Interleukin-10
Lymphocytic choriomeningitis virus
Allografts
Transgenic Mice
Antigen Presentation
Antigens
Pancreas
Virus Diseases
Immunosuppressive Agents
Autoimmunity
Type 1 Diabetes Mellitus
Macrophages
Cytokines

Keywords

  • allograft
  • autoimmunity
  • diabetes mellitus
  • transgenic mice
  • viral infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. / Lee, Myung Shik; Wogensen, Lise; Shizuru, Judith; Oldstone, Michael B.A.; Sarvetnick, Nora.

In: Journal of Clinical Investigation, Vol. 93, No. 3, 03.1994, p. 1332-1338.

Research output: Contribution to journalArticle

Lee, Myung Shik ; Wogensen, Lise ; Shizuru, Judith ; Oldstone, Michael B.A. ; Sarvetnick, Nora. / Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. In: Journal of Clinical Investigation. 1994 ; Vol. 93, No. 3. pp. 1332-1338.
@article{ccee2cff53394404bb86b17796056bdc,
title = "Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction",
abstract = "IL-10 inhibits macrophage-dependent antigen presentation, cytokine production, and generation of allospecific cells in vitro. These findings have lead to the widespread expectation that IL-10 may be a useful immunosuppressive agent to inhibit allograft rejection or autoimmunity in vivo. We used two experimental paradigms to study effects of murine IL-10 on in vivo immune responses. First, fetal pancreata or adult pancreatic islets from transgenic mice expressing IL-10 in pancreatic β cells (Ins-IL-10 mice) were grafted across the MHC barrier to examine if IL-10 could inhibit allograft rejection. Second, Ins-IL-10 mice were crossed with transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) antigens in pancreatic β cells. These mice were infected with LCMV to elicit autoimmune diabetes, allowing us to ask if IL-10 protects islets from autoimmune destruction. We observed that allografts from IL-10-transgenic donors were rejected with comparable kinetics to the rejection of control nontransgenic allografts, indicating that IL-10 does not inhibit allograft rejection. After LCMV infection, IL-10 and LCMV antigen double transgenic mice developed diabetes earlier than LCMV antigen single transgenic littermates, suggesting that IL- 10 does not inhibit islet antigen presentation or recognition. Our results contrast to in vitro observations and suggest that IL-10 cannot overcome immune-mediated tissue destruction within the pancreas.",
keywords = "allograft, autoimmunity, diabetes mellitus, transgenic mice, viral infection",
author = "Lee, {Myung Shik} and Lise Wogensen and Judith Shizuru and Oldstone, {Michael B.A.} and Nora Sarvetnick",
year = "1994",
month = "3",
doi = "10.1172/JCI117092",
language = "English (US)",
volume = "93",
pages = "1332--1338",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction

AU - Lee, Myung Shik

AU - Wogensen, Lise

AU - Shizuru, Judith

AU - Oldstone, Michael B.A.

AU - Sarvetnick, Nora

PY - 1994/3

Y1 - 1994/3

N2 - IL-10 inhibits macrophage-dependent antigen presentation, cytokine production, and generation of allospecific cells in vitro. These findings have lead to the widespread expectation that IL-10 may be a useful immunosuppressive agent to inhibit allograft rejection or autoimmunity in vivo. We used two experimental paradigms to study effects of murine IL-10 on in vivo immune responses. First, fetal pancreata or adult pancreatic islets from transgenic mice expressing IL-10 in pancreatic β cells (Ins-IL-10 mice) were grafted across the MHC barrier to examine if IL-10 could inhibit allograft rejection. Second, Ins-IL-10 mice were crossed with transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) antigens in pancreatic β cells. These mice were infected with LCMV to elicit autoimmune diabetes, allowing us to ask if IL-10 protects islets from autoimmune destruction. We observed that allografts from IL-10-transgenic donors were rejected with comparable kinetics to the rejection of control nontransgenic allografts, indicating that IL-10 does not inhibit allograft rejection. After LCMV infection, IL-10 and LCMV antigen double transgenic mice developed diabetes earlier than LCMV antigen single transgenic littermates, suggesting that IL- 10 does not inhibit islet antigen presentation or recognition. Our results contrast to in vitro observations and suggest that IL-10 cannot overcome immune-mediated tissue destruction within the pancreas.

AB - IL-10 inhibits macrophage-dependent antigen presentation, cytokine production, and generation of allospecific cells in vitro. These findings have lead to the widespread expectation that IL-10 may be a useful immunosuppressive agent to inhibit allograft rejection or autoimmunity in vivo. We used two experimental paradigms to study effects of murine IL-10 on in vivo immune responses. First, fetal pancreata or adult pancreatic islets from transgenic mice expressing IL-10 in pancreatic β cells (Ins-IL-10 mice) were grafted across the MHC barrier to examine if IL-10 could inhibit allograft rejection. Second, Ins-IL-10 mice were crossed with transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) antigens in pancreatic β cells. These mice were infected with LCMV to elicit autoimmune diabetes, allowing us to ask if IL-10 protects islets from autoimmune destruction. We observed that allografts from IL-10-transgenic donors were rejected with comparable kinetics to the rejection of control nontransgenic allografts, indicating that IL-10 does not inhibit allograft rejection. After LCMV infection, IL-10 and LCMV antigen double transgenic mice developed diabetes earlier than LCMV antigen single transgenic littermates, suggesting that IL- 10 does not inhibit islet antigen presentation or recognition. Our results contrast to in vitro observations and suggest that IL-10 cannot overcome immune-mediated tissue destruction within the pancreas.

KW - allograft

KW - autoimmunity

KW - diabetes mellitus

KW - transgenic mice

KW - viral infection

UR - http://www.scopus.com/inward/record.url?scp=0028280636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028280636&partnerID=8YFLogxK

U2 - 10.1172/JCI117092

DO - 10.1172/JCI117092

M3 - Article

C2 - 8132775

AN - SCOPUS:0028280636

VL - 93

SP - 1332

EP - 1338

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -